Apply for research funding from the CMT Research Foundation to advance therapies and cures for Charcot-Marie-Tooth disease. Global researchers, clinicians, and biotech companies are eligible.
The CMT Research Foundation (CMTRF) is dedicated to finding treatments and cures for Charcot-Marie-Tooth disease (CMT) within our lifetime. Through targeted and strategic funding, the foundation supports the most promising scientific projects that aim to translate discoveries into real-world therapeutic solutions for all CMT types.
Founded with a clear mission to bridge the gap between laboratory science and patient impact, CMTRF works with leading researchers, universities, and biotech companies worldwide. Its funding model emphasizes collaboration, innovation, and measurable progress toward developing CMT therapies.
The CMT Research Foundation welcomes applications from researchers and organizations pursuing approaches that align with its mission. While the foundation prioritizes projects based on its research agenda, creative and high-potential ideas are also considered.
Average Award Amount: USD 100,000 – 200,000 per year (larger budgets considered for exceptional proposals)
Award Duration: 1–3 years, with the possibility of follow-on funding
Eligible Applicants:
Academic institutions and medical research centers
Non-profit and for-profit research organizations
Biotechnology companies with an interest in CMT therapeutics
Funding may be provided to for-profit organizations when their projects align with CMTRF’s mission. Co-funding and cost-sharing with other agencies, investors, or industry partners are highly encouraged.
The foundation supports projects addressing:
Therapeutic development for all CMT subtypes
Translational studies that advance preclinical or clinical readiness
Collaborative models bridging academia and industry
Learn more about CMTRF’s approach and research priorities on their official website.
Before submitting a full proposal, applicants must first submit a Letter of Intent (LOI). Invitations to submit a full proposal are typically issued three weeks after LOI submission, allowing time to refine the application based on feedback from the CMTRF Scientific Advisory Board (SAB).
Applicants are strongly encouraged to submit the LOI early to allow ample time for revisions and proposal preparation.
Q1: December 17, 2025
Q2: February 18, 2026
Q3: May 20, 2026
Q4: August 12, 2026
LOIs submitted less than six weeks before these deadlines may be deferred to the following cycle at CMTRF’s discretion.
Submit a 1–2 page PDF highlighting:
Project aims and expected milestones
Potential collaborations or co-funding arrangements
Alignment with CMTRF’s mission and strategic goals
Submit your Letter of Intent via the online portal:
Submit LOI Here
Upon invitation, applicants must prepare a detailed proposal (PDF format) including:
Lay Summary and Scientific Rationale
Specific Aims and Background
Preliminary Data and Experimental Plan
Detailed Budget and Justification
Gantt Chart of Proposed Work
NIH Biosketches and Other Support documents
Feedback is typically provided within 3–8 weeks after submission.
Indirect costs are capped at 10%.
To stimulate early-stage innovation, the Emerging Researcher Award provides smaller, high-impact grants targeting key barriers in CMT drug development.
Two funding tracks are available:
Predoctoral Grants: Open to current PhD or MD students conducting CMT research.
Pilot Grants: Open to postdoctoral fellows and early-career investigators in academia or industry.
This program supports promising young scientists in producing preliminary data that can lead to larger CMT-focused projects. Collaborative efforts between academic and industry partners are strongly encouraged.
For full details, visit the Emerging Researcher Award page.
The CMT Research Foundation employs an iterative application process, allowing applicants to receive constructive feedback from CMT and industry experts. This approach ensures that every funded project has a clear path to translational or clinical impact.
Proposals are reviewed by the Scientific Advisory Board (SAB), which evaluates:
Scientific and therapeutic relevance
Feasibility and innovation
Research milestones and impact potential
Collaboration with industry or cross-institutional partners
All funding decisions are contingent on the successful negotiation of contract terms between CMTRF and the awardee institution. Progress is tracked against milestone-based deliverables, and continuation of funding depends on satisfactory performance and data outcomes.
Awardees must submit periodic progress and financial reports, ensuring accountability and alignment with the foundation’s mission.
Indirect costs up to 10% are permitted within the total project budget.
For program-related inquiries or questions about application requirements, contact:
Kate Andersh
Email: kate.andersh@cmtrf.org
To stay updated on future funding rounds and news, visit: https://cmtrf.org
Researchers and organizations interested in applying should:
Prepare and submit a Letter of Intent via the online portal as early as possible.
Upon invitation, develop a Full Proposal including all required sections and supporting materials.
Submit before one of the quarterly deadlines listed above.
Deadline: Apply as soon as possible (upcoming round closes December 17, 2025).
The CMT Research Foundation provides a unique opportunity to secure high-impact funding for innovative research with tangible patient outcomes. By fostering collaboration between academia, biotech, and clinical experts, CMTRF accelerates the discovery of therapies that can transform lives.
If your research has the potential to advance CMT treatment, this program offers both funding and expert guidance to help you translate ideas into impact.
For more international career opportunities, visit Opportunities For Youth.
Copyright 2025 Site. All rights reserved powered by Opportunities for Women
Comments are off for this post.